Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6751 to 6765 of 7669 results

  1. Nilotinib for the first line treatment of chronic myeloid leukaemia [ID79]

    Discontinued [GID-TAG408]

    Technology appraisal guidance
    Discontinued

  2. Psoriatic arthritis (moderate to severe) - leflunomide [ID391]

    Discontinued [GID-TAG385]

    Technology appraisal guidance
    Discontinued

  3. Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]

    In development [GID-TA10575] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076]

    In development [GID-TA10961] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Olaparib for maintenance treatment of BRCA-negative platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer [ID6205]

    In development [GID-TA10965] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Diabetic retinopathy - ruboxistaurin [ID382]

    In development [GID-TAG386] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Atrial fibrillation - idraparinux sodium [ID375]

    Discontinued [GID-TAG383]

    Technology appraisal guidance
    Discontinued

  8. Cardiovascular events (prevention, high risk) - anacetrapib [ID1164]

    Discontinued [GID-TA11176]

    Technology appraisal guidance
    Discontinued

  9. Osteoarthritis - diacerein [ID332]

    Discontinued [GID-TAG250]

    Technology appraisal guidance
    Discontinued

  10. Nivolumab monotherapy for non-small-cell lung cancer [ID1088]

    Discontinued [GID-TA10148]

    Technology appraisal guidance
    Discontinued

  11. Multiple sclerosis (primary-progressive) - fingolimod [ID62]

    Discontinued [GID-TAG221]

    Technology appraisal guidance
    Discontinued

  12. Human Growth Hormone for Idiopathic Short Stature (in children)[ID317]

    Discontinued [GID-TA11256]

    Technology appraisal guidance
    Discontinued

  13. Venous thromboembolism (recurrent) - idraparinux sodium [ID395]

    Discontinued [GID-TAG384]

    Technology appraisal guidance
    Discontinued

  14. Sacubitril valsartan for treating chronic heart failure with preserved ejection fraction [ID1606]

    Discontinued [GID-TA11257]

    Technology appraisal guidance
    Discontinued

  15. Heart failure (acute decompensated) - nesiritide [ID384]

    Discontinued [GID-TAG376]

    Technology appraisal guidance
    Discontinued